Page last updated: 2024-09-05

deferasirox and Experimental Hepatoma

deferasirox has been researched along with Experimental Hepatoma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujisawa, K; Hidaka, I; Ishikawa, T; Iwamoto, T; Maeda, M; Matsumoto, T; Saeki, I; Sakaida, I; Takami, T; Tani, K; Uchida, K; Yamamoto, N; Yamasaki, T1
Aihara, Y; Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Shirai, Y; Tsujimoto, T; Yanase, K; Yoshii, J; Yoshiji, H1
Brissot, P; Chantrel-Groussard, K; Gaboriau, F; Lescoat, G; Nick, H; Pasdeloup, N1

Trials

1 trial(s) available for deferasirox and Experimental Hepatoma

ArticleYear
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2016, Oct-28, Volume: 22, Issue:40

    Topics: Aged; Aged, 80 and over; Animals; Benzoates; Carcinoma, Hepatocellular; Deferasirox; Drug Screening Assays, Antitumor; Female; Hep G2 Cells; Humans; Iron Chelating Agents; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Middle Aged; Triazoles

2016

Other Studies

2 other study(ies) available for deferasirox and Experimental Hepatoma

ArticleYear
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
    American journal of physiology. Gastrointestinal and liver physiology, 2011, Volume: 300, Issue:6

    Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzoates; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Choline Deficiency; Deferasirox; Disease Progression; Drug Therapy, Combination; Fatty Liver; Hepatic Stellate Cells; Iron Chelating Agents; Liver Cirrhosis, Experimental; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Rats, Inbred F344; Time Factors; Transforming Growth Factor beta1; Triazoles

2011
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
    Cell proliferation, 2007, Volume: 40, Issue:5

    Topics: Animals; Apoptosis; Base Sequence; Benzoates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Deferasirox; Deferiprone; DNA Primers; DNA Replication; Humans; Iron Chelating Agents; Liver Neoplasms; Liver Neoplasms, Experimental; Polyamines; Pyridones; Rats; Triazoles

2007